Tools
Tools
Vincent, Tonia L., Alliston, Tamara, Kapoor, Mohit, Loeser, Richard F., Troeberg, Linda 
ORCID: https://orcid.org/0000-0003-0939-4651 and Little, Christopher B.
(2022)
Osteoarthritis pathophysiology: Therapeutic target discovery may require a multifaceted approach.
Clinics in Geriatric Medicine, 38 (2).
pp. 193-219.
ISSN 0749-0690
Preview |
PDF (CH0002_Vincent)
- Accepted Version
Available under License Creative Commons Attribution Non-commercial No Derivatives. Download (1MB) | Preview |
| Item Type: | Article |
|---|---|
| Additional Information: | Funding Information: T.L. Vincent has received research funding to support the STEpUP OA Consortium from Pfizer , Galapagos , Fidia , Novartis , BioSplice . T. Alliston, M. Kapoor and L. Troeberg have nothing to disclose. R.F. Loeser has received consulting fees from Unity Biotechnology. C.B. Little has provided consulting advice for Merck Serono and Galapagos Pharmaceuticals, and has received research funding from numerous pharmaceutical companies through specific services/testing contract research agreements between and managed by The University of Sydney or the Northern Sydney Local Health District. Funding Information: The research of the authors related to the specific topics explored in this review were supported by funding from numerous sources: T.L. Vincent Center for OA Pathogenesis versus Arthritis (grant no. 20205 and 21,621); M. Kapoor Tier 1 Canada Research Chair Award (#950?232237) and Tony and Shari Fell Platinum Chair in Arthritis Research; R.F. Loeser National Institute on Aging RO1 AG044034; L. Troeberg VA grants 21,776 and 22,194; C.B. Little Australian National Health and Medical Research Council (NHMRC: Project Grant APP1045890), the Hillcrest Foundation through Perpetual Philanthropies, and Arthritis Australia.T.L. Vincent has received research funding to support the STEpUP OA Consortium from Pfizer, Galapagos, Fidia, Novartis, BioSplice. T. Alliston, M. Kapoor and L. Troeberg have nothing to disclose. R.F. Loeser has received consulting fees from Unity Biotechnology. C.B. Little has provided consulting advice for Merck Serono and Galapagos Pharmaceuticals, and has received research funding from numerous pharmaceutical companies through specific services/testing contract research agreements between and managed by The University of Sydney or the Northern Sydney Local Health District. Funding Information: The research of the authors related to the specific topics explored in this review were supported by funding from numerous sources: T.L. Vincent Center for OA Pathogenesis versus Arthritis (grant no. 20205 and 21,621 ); M. Kapoor Tier 1 Canada Research Chair Award (#950–232237) and Tony and Shari Fell Platinum Chair in Arthritis Research; R.F. Loeser National Institute on Aging RO1 AG044034 ; L. Troeberg VA grants 21,776 and 22,194; C.B. Little Australian National Health and Medical Research Council (NHMRC: Project Grant APP1045890), the Hillcrest Foundation through Perpetual Philanthropies, and Arthritis Australia. |
| Uncontrolled Keywords: | aging,bone,cartilage,fibrosis,inflammation,osteoarthritis,pathophysiology,treatment targets,geriatrics and gerontology ,/dk/atira/pure/subjectarea/asjc/2700/2717 |
| Faculty \ School: | Faculty of Medicine and Health Sciences > Norwich Medical School |
| UEA Research Groups: | Faculty of Medicine and Health Sciences > Research Centres > Metabolic Health |
| Related URLs: | |
| Depositing User: | LivePure Connector |
| Date Deposited: | 20 Apr 2022 09:30 |
| Last Modified: | 25 Oct 2024 11:30 |
| URI: | https://ueaeprints.uea.ac.uk/id/eprint/84696 |
| DOI: | 10.1016/j.cger.2021.11.015 |
Downloads
Downloads per month over past year
Actions (login required)
 |
View Item |